Lemtrada 12 mg/1.2 mL Concentrate for solution for infusion
PDF Leaflet Revision Date: 20 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of highly active relapsing remitting multiple sclerosis (RRMS).
Dosage (summary)
12 mg/day IV infusion for 5 days, then 12 mg/day for 3 days after 12 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding should be discontinued during treatment and for 4 months after.
Key Drug Interactions
- Corticosteroids
- Beta interferon
- Glatiramer acetate
Contraindications
- Hypersensitivity to alemtuzumab
- HIV infection
- Severe active infection
- Uncontrolled hypertension
- History of arterial dissection
- History of stroke
- History of angina or myocardial infarction
- Coagulopathy or anticoagulant therapy
Common side effects
- Headache
- Rash
- Nausea
- Fatigue
- Thyroid disorders
- Infections
Counselling Points
- Monitor for signs of infection and autoimmune disorders.
- Educate on symptoms of serious adverse reactions.
- Adhere to follow-up and monitoring requirements.
Serious warnings
- Autoimmunity risk
- Infusion reactions
- Serious infections
- Thrombotic thrombocytopenic purpura
- Autoimmune hepatitis
Important Disclaimer
The Lemtrada 12 mg/1.2 mL Concentrate for solution for infusion professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
